Literature DB >> 32749512

Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants.

Ahmed Gabr1, Ahsun Riaz1, Guy E Johnson2, Edward Kim3, Siddharth Padia4, Robert J Lewandowski1, Riad Salem5.   

Abstract

PURPOSE: To study the correlation between absorbed perfused liver dose using Y90 radioembolization and degree of hepatocellular carcinoma (HCC) necrosis in liver explants in a multicenter cohort analysis
METHODS: A retrospective analysis of 45 HCC patients treated between 2014 and 2017 is presented. Inclusion criteria were treatment-naïve solitary HCC ≤ 8 cm and Child-Pugh A liver status using the radiation segmentectomy approach. All patients underwent liver resection or transplantation (LT). Liver explants were examined per institutional routine protocols to assess histopathological viability of HCC. Tumor pathological necrosis was classified into complete (100% necrosis), extensive (> 50% and ≤ 99%) necrosis, and partial (< 50%) necrosis. Absorbed perfused liver doses were estimated using MIRD calculations. Associations between dose and degree of necrosis were studied.
RESULTS: Thirty-four (76%) patients underwent LT, and 11 (24%) patients underwent hepatic resection. Median radiation dose was 240 (IQR: 136-387) Gy. Thirty (67%) patients had complete pathologic necrosis (CPN) at explant, while 10 (22%) and 5 (11%) had extensive and partial necrosis, respectively. There were significant differences among perfused liver doses that exhibited partial, extensive, and complete necrosis (p = 0.001). Twenty-four out of twenty-eight (86%) patients who had dose > 190 Gy achieved CPN, while 11/17 (65%) who had < 190 Gy did not (Fisher's exact test; p = 0.001). Using binary logistic regression, only absorbed radiation dose was significantly associated with CPN (p = 0.01), while tumor size was not (p = 0.35). All patients receiving > 400 Gy exhibited CPN.
CONCLUSION: Radiation segmentectomy for early HCC with ablative dosing > 400 Gy results in CPN. This represents the new standard target dose for radiation segmentectomy.

Entities:  

Keywords:  Radiation segmentectomy; Transplantation; Yttrium-90

Year:  2020        PMID: 32749512     DOI: 10.1007/s00259-020-04976-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  7 in total

1.  Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Jon Bell; Carlo Chiesa; Kirk Fowers; Bonnie Hamilton; Joseph Herman; S Cheenu Kappadath; Thomas Leung; Lorraine Portelance; Daniel Sze; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-16       Impact factor: 9.236

2.  Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.

Authors:  Robert J Lewandowski; Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Ali Al Asadi; Ronald A Mora; Laura Kulik; Daniel Ganger; Kush Desai; Bartley Thornburg; Samdeep Mouli; Ryan Hickey; Juan Carlos Caicedo; Michael Abecassis; Ahsun Riaz; Riad Salem
Journal:  Radiology       Date:  2018-04-24       Impact factor: 11.105

3.  Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study.

Authors:  Derek M Biederman; Joseph J Titano; Vivian L Bishay; Raisa J Durrani; Etan Dayan; Nora Tabori; Rahul S Patel; Francis S Nowakowski; Aaron M Fischman; Edward Kim
Journal:  Radiology       Date:  2016-12-07       Impact factor: 11.105

4.  Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.

Authors:  Michael Vouche; Laura Kulik; Rohi Atassi; Khairuddin Memon; Ryan Hickey; Daniel Ganger; Frank H Miller; Vahid Yaghmai; Michael Abecassis; Talia Baker; Mary Mulcahy; Ritu Nayar; Robert J Lewandowski; Riad Salem
Journal:  Hepatology       Date:  2013-10-01       Impact factor: 17.425

5.  Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres.

Authors:  Ahsun Riaz; Laura Kulik; Robert J Lewandowski; Robert K Ryu; Georgia Giakoumis Spear; Mary F Mulcahy; Michael Abecassis; Talia Baker; Vanessa Gates; Ritu Nayar; Frank H Miller; Kent T Sato; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

6.  Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation.

Authors:  Ahmed Gabr; Srirajkumar Ranganathan; Samdeep K Mouli; Ahsun Riaz; Vanessa L Gates; Laura Kulik; Daniel Ganger; Haripriya Maddur; Christopher Moore; Elias Hohlastos; Nitin Katariya; Juan Carlos Caicedo; Aparna Kalyan; Robert J Lewandowski; Riad Salem
Journal:  J Hepatol       Date:  2020-03-05       Impact factor: 25.083

7.  Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.

Authors:  Michael Vouche; Ali Habib; Thomas J Ward; Edward Kim; Laura Kulik; Daniel Ganger; Mary Mulcahy; Talia Baker; Michael Abecassis; Kent T Sato; Juan-Carlos Caicedo; Jonathan Fryer; Ryan Hickey; Elias Hohlastos; Robert J Lewandowski; Riad Salem
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

  7 in total
  16 in total

Review 1.  Yttrium-90 Radiation Segmentectomy.

Authors:  Guy E Johnson; Siddharth A Padia
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 2.  Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma.

Authors:  Zersenay Alem; Timothy E Murray; Csilla Egri; John Chung; David Liu; Khaled M Elsayes; Silvia D Chang; Alison Harris
Journal:  Abdom Radiol (NY)       Date:  2021-04-28

Review 3.  The Role of Catheter-Directed CT-Angiography in Radioembolisation.

Authors:  Kun Da Zhuang; Aaron Kian-Ti Tong; David Chee Eng Ng; Kiang Hiong Tay
Journal:  Cardiovasc Intervent Radiol       Date:  2022-05-20       Impact factor: 2.740

Review 4.  TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC.

Authors:  Boris Guiu; Etienne Garin; Carole Allimant; Julien Edeline; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2022-02-11       Impact factor: 2.740

5.  Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Carlo Chiesa; Paul Haste; Bruno Sangro; Beau Toskich; Kirk Fowers; Joseph M Herman; S Cheenu Kappadath; Thomas Leung; Daniel Y Sze; Edward Kim; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-17       Impact factor: 10.057

Review 6.  Principles of Radioembolization.

Authors:  Gajan Sivananthan; Nora E Tabori
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

Review 7.  Radioembolization for the Treatment of Hepatocellular Carcinoma: The Road to Personalized Dosimetry and Ablative Practice.

Authors:  Cynthia De la Garza-Ramos; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

8.  Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors.

Authors:  S Ali Montazeri; Cynthia De la Garza-Ramos; Andrew R Lewis; Jason T Lewis; Jordan D LeGout; David M Sella; Ricardo Paz-Fumagalli; Zlatko Devcic; Charles A Ritchie; Gregory T Frey; Lucas Vidal; Kristopher P Croome; J Mark McKinney; Denise Harnois; Sunil Krishnan; Tushar Patel; Beau B Toskich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-20       Impact factor: 10.057

9.  Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.

Authors:  Riad Salem; Guy E Johnson; Edward Kim; Ahsun Riaz; Vivian Bishay; Eveline Boucher; Kirk Fowers; Robert Lewandowski; Siddharth A Padia
Journal:  Hepatology       Date:  2021-06-11       Impact factor: 17.425

10.  Biochemical Safety of Ablative Yttrium-90 Radioembolization for Hepatocellular Carcinoma as a Function of Percent Liver Treated.

Authors:  Cynthia De la Garza-Ramos; Cameron J Overfield; S Ali Montazeri; Harris Liou; Ricardo Paz-Fumagalli; Gregory T Frey; J Mark McKinney; Charles A Ritchie; Zlatko Devcic; Andrew R Lewis; Denise M Harnois; Tushar Patel; Beau B Toskich
Journal:  J Hepatocell Carcinoma       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.